Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
|
|
Revance Therapeutics, Inc. (RVNC)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 5.5% stake in Revance Therapeutics Inc. |
| 02/03/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/27/2023 |
SC 13G/A
| JPMORGAN CHASE & CO reports a 6% stake in Revance Therapeutics, Inc. |
| 12/09/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2022 |
SC 13G/A
| Palo Alto Investors LP reports a 6.1% stake in Revance Therapeutics, Inc. |
| 02/08/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/04/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/03/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/18/2022 |
SC 13G/A
| JPMORGAN CHASE & CO reports a 9.4% stake in Revance Therapeutics, Inc. |
| 02/16/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/12/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2021 |
SC 13G/A
| Essex Woodlands Health Ventures VIII, L.L.C. reports a 0% stake in REVANCE THERAPEUTICS, INC. |
| 02/05/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/04/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/02/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/29/2021 |
SC 13G/A
| JPMORGAN CHASE & CO reports a 6.1% stake in Revance Therapeutics, Inc. |
| 08/10/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/06/2020 |
SC 13G/A
| BlackRock Inc. reports a 7.2% stake in REVANCE THERAPEUTICS INC |
| 02/05/2020 |
SC 13G/A
| FRANKLIN RESOURCES INC reports a 6.7% stake in Revance Therapeutics, Inc. |
| 01/17/2020 |
SC 13G/A
| JPMORGAN CHASE & CO reports a 7.9% stake in Revance Therapeutics, Inc. |
| 01/08/2020 |
SC 13G/A
| WELLINGTON MANAGEMENT GROUP LLP reports a 11.4% stake in Revance Therapeutics, Inc. |
| 11/12/2019 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 08/12/2019 |
SC 13G/A
| Bank of New York Mellon Corp reports a 4.8% stake in Revance Therapeutics, Inc. |
| 02/13/2019 |
SC 13G/A
| Essex Woodlands Health Ventures VIII, L.L.C. reports a 9% stake in REVANCE THERAPEUTICS, INC. |
| 02/12/2019 |
SC 13G/A
| NovaQuest Pharma Opportunities Fund III, L.P. reports a 4.2% stake in – Exit Filing)* Revance Therapeutics, Inc. |
| 02/12/2019 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/06/2019 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/29/2019 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/28/2019 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/04/2019 |
SC 13G/A
| JPMORGAN CHASE & CO reports a 10.2% stake in Revance Therapeutics, Inc. |
| 04/10/2018 |
SC 13G/A
| WELLINGTON MANAGEMENT GROUP LLP reports a 10.4% stake in Revance Therapeutics, Inc. |
|
|
|